Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells

Xu, Xiao-Jun; Tang, Yong-Min

doi:10.1016/j.canlet.2013.10.004

Cited by 156CAR-T cell therapy researchImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells

Xu, Xiao-Jun, Tang, Yong-Min·2014·Cancer Letters

DOI 10.1016/j.canlet.2013.10.004

Open this paper in CoChat — free account

Abstract

Adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells is a promising therapy for cancers. However, the safety of this approach is concerned. Cytokine release syndrome (CRS) is a common but lethal complication of CAR-T cell therapy. The development of CRS correlates with CAR structures, tumor type and burden, and patients' genetic polymorphisms. CRS related adverse events may be reduced by designing safer CARs and CAR-T cells and following strict dose-escalation scheme. Timely and effective cytokine-directed treatment with corticosteroid and various cytokine antagonists is important to avoid CRS associated death.

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2013.10.004

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Additional factors such as CAR structure and design, disease burden, and host genomic background are likely to play a part in whether cytokine storm develops in patients treated with CAR T cells or blinatumomab.
“However, cytokine storm does not develop in all patients treated with CAR T cells or blinatumomab, so additional factors, such as CAR structure and design,51 disease burden,58 and host genomic background,59 are likely to play a part.”
From Cytokine storm (2020) · cites this paper as [51]

HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Henter, J., Horne, A., Aricò, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., McClain, K. L., Webb, D. K. H., Winiarski, J. H., et al. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.21039 · Cited by 5,396 · see citing works
Cellular and Molecular Immunology
Abbas, A. K., Lichtman, A. H., & Pillai, S. S. (1994) · Cited by 3,571 · see citing works
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works
Cellular and Molecular Immunology
Denman, A. M. (1992) · Postgraduate Medical Journal · doi:10.1136/pgmj.68.798.305 · Cited by 2,805 · see citing works
TRANSCRIPTION FACTORS OF THE NFAT FAMILY:Regulation and Function
Rao, A., Luo, C. H., & Hogan, P. G. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.707 · Cited by 2,592 · see citing works
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,389 · see citing works
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 2× · see citing works
“The anti-IL-2 receptor antagonist antibody has been administrated with high-dose methylprednisolone to treat the CRS induced by TGN1412 [23].”
Background
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · see citing works
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · see citing works
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.
de Jong, M. D., Simmons, C. P., Thanh, T. T., Hien, V. M., Smith, G. J. D., Chau, T. N. B., Hoang, D. M., Van Vinh Chau, N., Khanh, T. H., Dong, V. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1477 · Cited by 1,858 · see citing works
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,668 · see citing works
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D., Marić, I., Stetler‐Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,441 · see citing works
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,287 · see citing works
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · see citing works
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Louis, C. U., Savoldo, B., Dotti, G., Pulè, M. A., Yvon, E. S., Myers, G. D., Rössig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,162 · see citing works
How I treat hemophagocytic lymphohistiocytosis
Jordan, M. B., Allen, C. E., Weitzman, S. S., Filipovich, A. H., & McClain, K. L. (2011) · Blood · doi:10.1182/blood-2011-03-278127 · Cited by 1,145 · see citing works
Tumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. R. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076 · see citing works
The Tumor Lysis Syndrome
Howard, S. C., Jones, D. P., & Pui, C.-H. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0904569 · Cited by 1,044 · see citing works
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023 · see citing works
An inducible caspase 9 safety switch for T-cell therapy
Straathof, K. C. M., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 745 · see citing works
Mechanisms of sepsis-induced cardiac dysfunction
Rudiger, A., & Singer, M. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000266683.64081.02 · Cited by 696 · see citing works
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657 · see citing works
First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation
Martin, P. J., Rizzo, J. D., Wingard, J. R., Ballen, K. K., Curtin, P. T., Cutler, C. S., Litzow, M. R., Nieto, Y. L., Savani, B. N., Schriber, J. R., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.04.005 · Cited by 641 · see citing works
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613 · see citing works
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.
Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., Bordignon, C., Peccatori, J., Ciceri, F., et al. (2013) · Blood · doi:10.1182/blood-2012-05-431718 · Cited by 611 · see citing works
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Kolb, H. (2008) · Blood · doi:10.1182/blood-2008-03-077974 · Cited by 587 · see citing works
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J. F., Heslop, H., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 568 · see citing works
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Hudecek, M., Stanghellini, M. T. L., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C. M., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 543 · see citing works
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 531 · see citing works
Anti-Transgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Re-directed T Cells in Humans
Jensen, M., Popplewell, L., Cooper, L., Digiusto, D., Kalos, M., Ostberg, J., & Forman, S. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.014 · Cited by 522 · see citing works
Sepsis and Endothelial Permeability
Lee, W. L., & Slutsky, A. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmcibr1007320 · Cited by 516 · see citing works
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
Themeli, M., Kloss, C. C., Ciriello, G., Fedorov, V. D., Perna, F., Gonen, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2678 · Cited by 473 · see citing works
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Kochenderfer, J., & Rosenberg, S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 467 · see citing works
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
Schreiber, S., Fedorak, R. N., Nielsen, O. H., Wild, G., Williams, C. N., Nikolaus, S., Jacyna, M. R., Lashner, B. A., Gangl, A., Rutgeerts, P. J., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.20196 · Cited by 458 · see citing works
Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
Zhao, Y., Moon, E. K., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 448 · see citing works
The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome
Wang, H., & Ma, S. (2008) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2007.10.031 · Cited by 408 · see citing works
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
Brentjens, R. J., Yeh, R., Bernal, Y. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.31 · Cited by 380 · see citing works
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
Song, D.-G., Ye, Q., Poussin, M., Pritchard, G. H., Figini, M., & Powell, D. J. (2011) · Blood · doi:10.1182/blood-2011-03-344275 · Cited by 355 · see citing works
Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients
Stéphan, J.-L. (2001) · British journal of rheumatology · doi:10.1093/rheumatology/40.11.1285 · Cited by 328 · see citing works
Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock*
Oppert, M., Schindler, R., Husung, C., Offermann, K., Gräf, K.-J., Boenisch, O., Barckow, D., Frei, U. A., & Eckardt, K. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000186370.78639.23 · Cited by 326 · see citing works
IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION
Chatenoud, L., Ferran, C. J., Legendre, C. M., Thouard, I., Merite, S., REUTER, A. M., Gevaert, Y., Kreis, H., Franchimont, P., & Bach, J. (1990) · Transplantation · doi:10.1097/00007890-199004000-00009 · Cited by 319 · see citing works
In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
Song, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287 · see citing works
Sorting Through Subsets
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31827806e6 · Cited by 276 · see citing works
Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1.
Ferrara, J. L., Abhyankar, S., & Gilliland, D. G. (1993) · PubMed · Cited by 252 · see citing works
Diagnostic Accuracy of a Specific Cytokine Pattern in Hemophagocytic Lymphohistiocytosis in Children
Xu, X., Tang, Y., Song, H., Yang, S.-L., Xu, W., Zhao, N., Shi, S., Shen, H., Mao, J., Zhang, L., et al. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.11.046 · Cited by 227 · see citing works
Self-citation
Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell Transplantation
Tey, S., Dotti, G., Rooney, C. M., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.04.005 · Cited by 204 · see citing works
Neutralization of IFNγ defeats haemophagocytosis in LCMV‐infected perforin‐ and Rab27a‐deficient mice
Schmid, J. P., Ho, C. H., Chrétien, F. C., Lefebvre, J. M., Pivert, G., Kosco‐Vilbois, M. H., Ferlin, W. G., Geissmann, F., Fischer, A., & Basile, G. D. S. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900009 · Cited by 196 · see citing works
Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome
Tang, Y., Xu, X., Song, H., Yang, S., Shi, S., Wei, J., Pan, B., Zhao, F., Liao, C., & Luo, C. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07298.x · Cited by 186 · see citing works
Self-citation
PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE)
Basch, E., Reeve, B. B., Cleeland, C. S., Sloan, J., Schrag, D., Atkinson, T., Mendoza, T. R., Hay, J., Abernethy, A. P., Minasian, L. M., et al. (2010) · Value in Health · doi:10.1016/s1098-3015(11)72017-4 · Cited by 163 · see citing works
Monoclonal antibody-induced cytokine-release syndrome
Bugelski, P. J., Achuthanandam, R., Capocasale, R. J., Treacy, G., & Bouman‐Thio, E. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.31 · Cited by 161 · see citing works
A case of macrophage activation syndrome successfully treated with anakinra
Kelly, A., & Ramanan, A. V. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0919 · Cited by 147 · see citing works
Rapid and Sustained Remission of Systemic Juvenile Idiopathic Arthritis-Associated Macrophage Activation Syndrome Through Treatment With Anakinra and Corticosteroids
Brück, N., Suttorp, M., Kabus, M., Heubner, G., Gahr, M. L., & Peßler, F. (2011) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e318205092d · Cited by 142 · see citing works
A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
Kandalaft, L. E., Powell, D. J., & Coukos, G. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-157 · Cited by 124 · see citing works
Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia
Barrett, D. M., Liu, X., Jiang, S., June, C. H., Grupp, S. A., & Zhao, Y. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.075 · Cited by 111 · see citing works
Genetic polymorphisms in sepsis
Dahmer, M. K., Randolph, A., Vitali, S., & Quasney, M. W. (2005) · Pediatric Critical Care Medicine · doi:10.1097/01.pcc.0000161970.44470.c7 · Cited by 101 · see citing works
Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma
Shen, C.-J., Yang, Y.-X., Han, E. Q., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-33 · Cited by 100 · see citing works
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
Han, E. Q., Li, X., Wang, C., Li, T.-F., & Han, S. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-47 · Cited by 79 · see citing works
Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010
Ertl, H. C. J., Zaia, J. A., Rosenberg, S. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4035 · Cited by 66 · see citing works
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group
Lacy, M. Q., Jacobus, S. J., Blood, E., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.020 · Cited by 57 · see citing works
Inflammatory cytokine measurement quickly discriminates gram-negative from gram-positive bacteremia in pediatric hematology/oncology patients with septic shock
Xu, X., Tang, Y., Liao, C., et al. (2012) · Intensive Care Medicine · doi:10.1007/s00134-012-2752-4 · Cited by 56 · see citing works
Self-citation
T-cell activation by recombinant immunoreceptors: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells
Heuser-Loy, C., Hombach, A. A., Lösch, C., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302023 · Cited by 53 · see citing works
Re-evaluation of Benefits of BRCA1/2 Testing
Knell, E. R., Presant, C. A., Grann, V. R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1962 · Cited by 52 · see citing works
Improving the efficacy and safety of engineered T cell therapy for cancer
Shi, H., Liu, L., & Wang, Z. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.015 · Cited by 47 · see citing works
Human effector T cells derived from central memory cells rather than CD8+T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy
Wu, F., Zhang, W., Shao, H., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.06.009 · Cited by 43 · see citing works
Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials
Xu, X., Zhao, H., & Tang, Y.-M. (2013) · Leukemia and Lymphoma · doi:10.3109/10428194.2012.715350 · Cited by 41 · see citing works
Self-citation
Correction: Online Publication Dates for Cancer Research May 1, 2011 Articles
(2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1396 · Cited by 28 · see citing works
Cytokines in human health : immunotoxicology, pathology, and therapeutic applications
House, R. V., & Descotes, J. (2007) · Cited by 27 · see citing works
Adoptive T-cell therapy of B-cell malignancies: Conventional and physiological chimeric antigen receptors
Liu, L., Sun, M., & Wang, Z. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.027 · Cited by 22 · see citing works
Flu-Like Syndrome and Cytokines
Descotes, J., & Vial, T. (2007) · Methods in pharmacology and toxicology · doi:10.1007/978-1-59745-350-9_10 · Cited by 19 · see citing works
Inflammatory Cytokines and Lung Toxicity
Laskin, D. L., Sunil, V. R., Laumbach, R. J., & Kipen, H. M. (2007) · Methods in pharmacology and toxicology · doi:10.1007/978-1-59745-350-9_6 · Cited by 9 · see citing works
Clinical Adverse Effects of Cytokines on the Immune System
Vial, T., & Descotes, J. (2007) · Methods in pharmacology and toxicology · doi:10.1007/978-1-59745-350-9_16 · Cited by 9 · see citing works
Cytokine-Induced Vascular Leak Syndrome
Baluna, R. G. (2007) · Methods in pharmacology and toxicology · doi:10.1007/978-1-59745-350-9_11 · Cited by 8 · see citing works
A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.
Lin, T. S., Lucas, M. S., Heerema, N. A., et al. (2006) · Blood · doi:10.1182/blood.v108.11.2841.2841 · Cited by 8 · see citing works

Flagged first, then by citations

Sorted by citations

Cytokine storm
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196 · see citing works
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., Liu, Y., Huang, J., Lv, H., Luo, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440169 · Cited by 338 · see citing works

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
Riegler, L. L., Jones, G. P., & Lee, D. W. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s150524 · Cited by 146 · see citing works
Early and Late Toxicities of Chimeric Antigen Receptor T-Cells
Epperly, R., Giordani, V. M., Mikkilineni, L., & Shah, N. N. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.010 · Cited by 16 · see citing works
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
Kotch, C., Barrett, D. M., & Teachey, D. T. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1629904 · Cited by 322 · see citing works
Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy
Chou, C. K., & Turtle, C. J. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0602-5 · Cited by 72 · see citing works
CAR T cells – the future for cancer therapy
Benjamin, R. (2021) · Medicine · doi:10.1016/j.mpmed.2021.02.012

Authors: Xu, X.-J., & Tang, Y.-M.
Venue: Cancer Letters
Publisher: Elsevier BV
Published: 2014-02
Volume: 343
Issue: 2
Pages: 172-178
ISSN: 0304-3835 (ISSN-L)
DOI: 10.1016/j.canlet.2013.10.004
OpenAlex: W1994594038
Cited by: 156
References: 75
Citations by year: 2026: 2 · 2025: 7 · 2024: 16 · 2023: 4 · 2022: 8 · 2021: 9 · 2020: 29 · 2019: 12 · 2018: 19 · 2017: 18 · 2016: 11 · 2015: 10 · 2014: 11
FWCI: 1.13
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Cancer Letters (publishedVersion)
PubMed (publishedVersion)
Funders: National Natural Science Foundation of China (30971283, 31100638, 81170502)
Ministry of Education of the People's Republic of China (20110101120138)
Natural Science Foundation of Zhejiang Province (LZ12H08001, Y2110020)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: cytokine release syndrome, chimeric antigen receptor T cells, CAR T-cell therapy, cancer immunotherapy, automotive design, dose escalation, corticosteroids, cytokine antagonists, adverse events, genetic polymorphism
MeSH terms: Humans, Immunotherapy, Neoplasms, Receptors, Antigen, T-Cell, Recombinant Fusion Proteins, Syndrome, Cytokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks